Table S3.
Parameters included in one-way sensitivity analysis
| Parameter/variable name | Description | Base-case input | Low value | High value |
|---|---|---|---|---|
| discH | Discount rate for health (%) | 0.035 | 0.028 | 0.042 |
| discC | Discount rate for cost (%) | 0.035 | 0.028 | 0.042 |
| iAge | Age (years) | 53.00 | 42.400 | 63.600 |
| pMale | Gender (% male) | 0.37 | 0.296 | 0.444 |
| TWSBline_NonResp | Mean baseline TWSTRS – nonresponders: abobotulinumtoxinA | 42.79 | 34.232 | 51.348 |
| TWSBline_Resp | Mean baseline TWSTRS – responders: abobotulinumtoxinA | 44.12 | 35.296 | 52.944 |
| TWSBline_BSC | Mean baseline TWSTRS – BSC | 43.63 | 34.902 | 52.353 |
| Coeff_TWS | Coefficient for TWSTRS | −0.02 | −0.019 | −0.013 |
| Coeff_Inter | Intercept | 1.26 | 1.004 | 1.506 |
| iReinj_PriNonResp | Number of reinjection attempts for primary nonresponders before abandoning treatment | 6.00 | 4.800 | 7.200 |
| iReinj_SecNonResp | Number of reinjection attempts for secondary nonresponders before abandoning treatment | 4.00 | 3.200 | 4.800 |
| TWSChangeAt4Wks_Abo_nonresponder | AbobotulinumtoxinA_TWSTRS change from baseline at 4 weeks – nonresponders | −0.61 | −0.643 | −0.583 |
| TWSChangeAt4Wks_Abo_fullresponder | AbobotulinumtoxinA _TWSTRS change from baseline at 4 weeks – responders | −20.29 | −22.290 | −18.290 |
| TWSChangeAt8Wks_Abo_nonresponder | AbobotulinumtoxinA _TWSTRS change from baseline at 8 weeks – nonresponders | −0.14 | −0.140 | −0.136 |
| TWSChangeAt8Wks_Abo_responder | AbobotulinumtoxinA _TWSTRS change from baseline at 8 weeks – responders | −18.30 | −20.300 | −16.300 |
| TWSChangeAt12Wks_Abo_nonresponder | AbobotulinumtoxinA _TWSTRS change from baseline at 12 weeks – nonresponders | −0.21 | −0.283 | −0.143 |
| TWSChangeAt12Wks_Abo_fullresponder | AbobotulinumtoxinA _TWSTRS change from baseline at 12 weeks – responders | −9.35 | −11.350 | −7.350 |
| TWSChangeAt4Wks_BSC | BSC_TWSTRS change from baseline at 4 weeks | −4.97 | −6.970 | −2.970 |
| TWSChangeAt8Wks_BSC | BSC_TWSTRS change from baseline at 8 weeks | −4.22 | −6.220 | −2.220 |
| TWSChangeAt12Wks_BSC | BSC_TWSTRS change from baseline at 12 weeks | −3.32 | −5.320 | −1.320 |
| distriFirstInj_Abo_nonresponder | Probability of nonresponse at first injection | 0.37 | 0.296 | 0.444 |
| distriFirstInj_Abo_responder | Probability of response at first injection | 0.63 | 0.504 | 0.756 |
| pAE_Abo | AE rate per injection: abobotulinumtoxinA (%) | 15% | 12% | 18% |
| dFirstInj_Abo | AbobotulinumtoxinA _first injection dosage: mean dose (unit) | 500.00 | 400.000 | 600.000 |
| dFirstInj_Ona | OnabotulinumtoxinA _first injection dosage: mean dose (unit) | 200.00 | 160.000 | 240.000 |
| dFirstInj_Inco | IncobotulinumtoxinA _first injection dosage: Mean dose (unit) | 200.00 | 160.000 | 240.000 |
| dReinj_Abo_nonresponder | Average abobotulinumtoxinA reinjection dosage: nonresponder (unit) | 750.00 | 600.000 | 900.000 |
| dReinj_Abo_responder | Average abobotulinumtoxinA reinjection dosage: responder (unit) | 400.00 | 320.000 | 480.000 |
| cDrugFirstInj_Abo | AbobotulinumtoxinA _first injection cost (£) | 154.00 | 123.200 | 184.800 |
| cDrugReinj_Abo_nonresponder | AbobotulinumtoxinA _reinjections cost – nonresponder (£) | 246.40 | 197.120 | 295.680 |
| cDrugReinj_Abo_fullresponder | AbobotulinumtoxinA _reinjections cost – responder (£) | 154.00 | 123.200 | 184.800 |
| cConMed_BoNTA | Concomitant Meds Cost_BoNTA (£) | 0.05 | 0.042 | 0.062 |
| cConMed_BSC | Concomitant Meds Cost _BSC (£) | 0.07 | 0.059 | 0.089 |
| cDrugAdmin | Cost Drug Admin (£) | 146.00 | 116.800 | 175.200 |
| cDisMgt_Abo | Cost Disease Management_AbobotulinumtoxinA (£) | 31.77 | 25.419 | 38.129 |
| cDisMgt_BSC | Cost Disease Management _BSC (£) | 113.31 | 90.645 | 135.967 |
| cAE | Cost AEs_BoNTA (£) | – | – | – |
| cIndirect_BoNTA | Cost Indirect_Abo (£) | 306.24 | 244.992 | 367.488 |
| cIndirect_BSC | Cost Indirect_BSC (£) | 765.60 | 612.480 | 918.720 |
| timeYearsInCycle_Abo | Reinjection Interval (years) | 0.23 | 0.184 | 0.276 |
Abbreviations: AE, adverse event; BoNTA, botulinum neurotoxin type A; BSC, best supportive care; TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale.